Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

INTERMEDIATES

2 Intermediates Suppliers

2 Intermediates Suppliers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

2INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1345847-93-9, Dcc-2701, Dp-5164, Altiratinib [usan], Altiratinib (usan), 1,1-cyclopropanedicarboxamide, n-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-

Molecular Formula

C₂₆H₂₁F₃N₄O₄

Molecular Weight

510.5 g/mol

InChI Key

GNNDEPIMDAZHRQ-UHFFFAOYSA-N

FDA UNII

T678746713

Altiratinib is an orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.

1 2D Structure

Altiratinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-N'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

2.1.2 InChI

InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)

2.1.3 InChI Key

GNNDEPIMDAZHRQ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F

2.2 Other Identifiers

2.2.1 UNII

T678746713

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Dcc-2701

2.3.2 Depositor-Supplied Synonyms

1. 1345847-93-9

2. Dcc-2701

3. Dp-5164

4. Altiratinib [usan]

5. Altiratinib (usan)

6. 1,1-cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-

7. 1,1-cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)-

8. N-(4-((2-((cyclopropylcarbonyl)amino)pyridin-4-yl)oxy)-2,5-difluorophenyi)-n-(4- Fluorophenyl)cyclopropane-1,1-dicarboxamide

9. T678746713

10. 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

11. N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.

12. N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

13. Unii-t678746713

14. Altiratinib;dcc2701

15. Altiratinib [inn]

16. Altiratinib(dcc-2701)

17. Altiratinib [who-dd]

18. Schembl139906

19. Gtpl9174

20. Chembl3545365

21. Dcc-270

22. Dcc2701

23. Ex-a902

24. Bcp15682

25. Hy-b0791

26. Bdbm50193395

27. Mfcd28900672

28. Nsc784590

29. S6412

30. Akos026750329

31. Zinc113198271

32. Cs-3944

33. Nsc-784590

34. Sb18876

35. Ncgc00480913-04

36. Ac-35383

37. N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

38. Ft-0700171

39. A14387

40. D10862

41. F11464

42. A887875

43. J-690136

44. Q27074416

45. 1,1-cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n-(4-fluorophenyl)-

46. 4-{5-[(e)-2-{4-(2-chlorophenyl)-5-[5-(methylsulfonyl)-2-pyridinyl]-4h-1,2,4-triazol-3-yl}vinyl]-1,3,4-oxadiazol-2-yl}benzonitrile

47. A9i

48. N-1'-[4-[2-(cyclopropylcarbonylamino)pyridin-4-yl]oxy-2,5-bis(fluoranyl)phenyl]-n-1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

2.4 Create Date

2011-12-05

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₁F₃N₄O₄
Molecular Weight	510.5 g/mol
XLogP3	4.3
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	8
Exact Mass	510.15148965 g/mol
Monoisotopic Mass	510.15148965 g/mol
Topological Polar Surface Area	109 Å²
Heavy Atom Count	37
Formal Charge	0
Complexity	863
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1